Most popular stories in October 2022

09-Nov-2022 - Last updated on 09-Nov-2022 at 11:20 GMT

Novo Nordisk, Sanofi, AstraZenec, Merck and Moderna, among others, feature in our round-up of top hitting stories last month. Photo Credit © GettyImages/PM Images

Related news

Once-weekly efanesoctocog alfa data shows ‘potential to transform the treatment landscape for hemophilia A’, says Sanofi
Sanofi announces boost to strategic venture fund
Moderna and CytomX partner up on mRNA-based conditionally activated therapeutics
Moderna to acquire OriCiro Genomics

Webinars

Upcoming supplier webinars

17 Sep 2024 Tue Manufacturing Friendly Aggregate Clearance in Downstream Processing of Bispecific and Traditional Antibodies Using a Novel POROS Mixed-Mode Chromatography Media Thermo Fisher Scientific - Biosciences

Headlines

Candid Therapeutics launches with $370m to tackle autoimmunity with T-cell engagers
Therapy for aggressive brain cancer receives FDA clearance to start phase 1
Neuromuscular diseases in crosshairs in Forge Biologics gene therapy collaboration
Lilly to collaborate with Haya Therapeutics to develop drugs for metabolic conditions
ArsenalBio bags $325 million to develop CRISPR-engineered cell therapies
European Commission grants orphan drug designation for rare disease gene therapy
Orgenesis touts early clinical promise of CAR-T therapy with decentralized production in mind
FDA grants expanded approval for Emergent Bio’s mpox vaccine
Positive Phase II booster results for Lyme disease vaccine candidate
AstraZeneca invests $135M on expanding biologics facility in Sweden
Neurocrine’s schizophrenia drug succeeds at phase 2, but dosing questions remain

Most popular stories in October 2022

Related news

Follow us

Webinars

Headlines

Follow us

BioPharma-Reporter

Resources